Risk stratification of sentinel lymph node biopsy (SNB)-positive patients with malignant melanoma differs among current classification systems. To improve classification of patients with rapidly progressive disease who may profit from adjuvant therapy with novel immune or targeted treatment modalities, a single-center retrospective analysis was performed including all melanoma patients diagnosed with a positive SN at a university-based skin cancer center over a 10-year period (2002-2012) (96 of 419 patients). Sentinel node metastasis mitotic rate (SN-MMR) and further histologic parameters were determined by blinded histological re-evaluation and correlated with clinical follow-up (overall [OS], melanoma-specific [MSS], and diseasefree survival [DFS]). Median follow-up was 53 months. In univariate analyses, SN tumor penetrative depth (TPD), maximum tumor diameter (MTD), number of positive SN, SN-MMR and the S-, Rotterdam, RDC, Hannover I and II classification systems correlated with OS, MSS and DFS. Multivariate Cox regression analyses showed that a binary classification system based only on the SN-MMR (<1 vs. 1 mitoses/mm 2 ) was the strongest independent prognostic indicator for all endpoints analyzed. Kaplan-Meier analyses confirmed binary SN-MMR to be superior to stratify patients into high-and low-risk groups (45.45% vs. 87.92% 5-yr MSS). The general prognostic validity of the published SN classification systems was confirmed. The novel SN-MMR classification system may improve discrimination of patients with slowly and rapidly progressive disease. We therefore propose its implementation into clinical practice as the SN-MMR can be easily and reliably determined in routine pathology reports. Its prognostic value for the selection of patients amenable to adjuvant therapies should be studied in clinical trials.
The sentinel lymph node biopsy (SNB) procedure as introduced by Morton et al.
1 is currently part of the routinely performed staging investigations for intermediate thickness melanomas in most countries. In Europe and U.S., it is usually recommended for melanomas with a Breslow thickness of at least 1.0 mm. 2, 3 SNB can also be considered for melanomas with a thickness of 0.75-0.99 mm when additional risk factors are present. 4, 5 In patients undergoing SNB, the presence or absence of metastasis in the SNB is considered the most important prognostic factor. 6 However, patients with a positive SNB still represent a very heterogeneous group with regard to prognosis. Therefore, various attempts were made to subclassify positive SN by histopathological features based on the maximum tumor diameter of the largest metastatic deposit (MTD), 7 tumor burden measurements, 8, 9 the tumor penetrative depth (TPD, measured from the capsule), 10 ,11 the microanatomic location, the presence of capsular involvement and/or the presence of extension to extra-nodal lymphatic vessels. Different cut-off points and various combinations of the aforementioned parameters have been proposed to guide prognostic classification 12, 13 and further management of the patients. Despite its prognostic power, a general benefit of the SNB with regard to overall survival has not been demonstrated yet. There is some indication for improved melanoma-specific survival of patients with intermediate thickness melanomas when assigned to SNB and immediate subsequent completion lymphadenectomy in comparison to patients undergoing nodal observation, but overall survival does not seem to be improved. 14, 15 However, with the increasing knowledge about dormant distant metastatic foci, locoregional treatment by completion lymphadenectomy with its high rate of side effects may not continue to be the treatment of choice in sentinel-positive melanoma patients. To evaluate novel systemic therapies as adjuvant treatment modalities in clinical trials, however, better risk stratification of sentinel node-positive melanoma patients is urgently needed. From this perspective, all SNB that were diagnosed as positive at our institution between 2002 and 2012 were retrospectively re-evaluated to compare the prognostic values of different histopathological parameters and classification systems with regard to overall, melanoma-specific and diseasefree survival. Similar to the staging classification of primary melanomas in the 2009 AJCC classification, we introduced the sentinel node metastasis mitotic rate (SN-MMR) as a novel, simple parameter for the prognostic risk stratification of SN-positive melanoma patients and compared it to the other classifications.
Material and Methods

Patients
A retrospective analysis including histopathologic reevaluation of melanoma patients diagnosed with a positive SNB at our institution (Skin cancer center, University Medical Center Mannheim) was performed. All patients diagnosed with a positive SNB between September 1, 2002 and January 31, 2012 were retrieved from the department's archives. During this period, 419 SNB procedures have been performed and 107 reports of positive SNB could be retrieved. A database with information on the past medical history, follow-up and pathologic features of the primary melanoma and SNB was generated. Due to technical reasons the slides of three patients were not sufficiently well-preserved for reevaluation. Six of the 107 cases were deemed negative on re-evaluation, either due to the diagnosis of a capsular nevus or due to false-positive interpretation of exogenous pigmentation or immunohistochemistry in the primary report. Two cases originally described as positive SNB in the report turned out to be macroscopic metastases already identified on ultrasonography or clinical exam and were also excluded. Therefore the analysis included clinical information, follow-up, and histopathologic reevaluation of 96 patients with positive SNB.
SNB procedure, tissue processing, and staining
The SNB procedure was performed following the triple technique. 16 After fixation in 4% paraformaldehyde the sentinel lymph node tissue was cut in approximately 1 mm thick slices oriented in parallel to the longitudinal axis of the lymph node. All tissue slices were then dehydrated and embedded in paraffin wax. The paraffin embedded tissue was then cut in 5 mm thick sections and stained by H&E, anti-HMB-45 and anti-Mart-1.
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Histopathology
The slides of all 96 available cases were re-evaluated by two board-certified dermatopathologists with long-standing experience in the evaluation of SNB of melanoma patients. assessed with the use of the hot spot method that is also recommended for primary melanomas. 18 In brief, an Olympus BX51 microscope was used. First, all metastatic tumor deposits were screened for mitotic activity and if mitoses were found their number per mm 2 was then determined in the area of the highest mitotic activity by counting mitotic figures in five adjacent high power fields (HPF) at a magnification of 400-fold (the diameter of one HPF measured 0.5 mm; the total area (A) of five HPF can therefore be calculated according to the following formula: A5 p3r ). To discriminate whether mitoses are to be attributed to inflammatory cells or melanoma cells, a correlation with the corresponding immunohistochemically (Mart-1/HMB-45) stained sections was performed. Only mitoses that were undoubtedly identified in melanoma cells were counted (Fig. 1) . Microscopic photographs were taken with a Nikon eclipse-Ci microscope and a Nikon DS-Fi2 camera. In cases with several positive lymph nodes, each positive lymph node was classified individually and the most advanced measurement or classification was then used for correlation with the outcome.
What's new? Sentinel node biopsy (SNB) can show whether melanoma has metastasized, but it does not improve overall survival, because there is wide variation in the aggressiveness of tumors that test positive. These authors hoped to improve outcomes by subclassifying melanomas with positive SNB. They retrospectively evaluated a decade's worth of sentinel node biopsies in search of a classifying characteristic that could help predict survival. They found that sentinel node metastasis mitotic rate could distinguish patients with rapidly progressing disease from those with slowly progressing disease. This simple and cost-effective test could help identify patients who would benefit from adjuvant therapy. SN classifications and histologic parameters were correlated with overall-, melanoma-specific, and disease-free survival by Log-rank test and by univariate Cox-regression. Furthermore, multiple Cox regression models have been used in order to test the influence of several parameters on the outcome simultaneously. Akaike information criteria (AIC) are given for these different models. The Akaike information criterion estimates the relative quality of a model, a lower value indicates a superior model. Thus the preferred model in order to explain a certain outcome variable is the model with the minimal AIC value. It is noteworthy that the AIC includes a penalty term 2k where k is the number of parameters in the model. Disease-free survival was defined as the time to the first occurrence of locoregional recurrence or emergence of additional lymphatic or distant metastases after SNB.
Statistics
The result of a statistical test has been considered as significant for p < 0.05. For p values between 0.05 and 0.10 a trend towards significance has been identified. All statistical calculations have been done with SAS software, release 9.3 (SAS Institute Inc., Cary, NC).
Results
Patient characteristics and histopathologic review
Between 2002 and 2012, 419 SNB procedures were performed on patients with melanoma at our department, 99 (23.6%) of these had a positive SN. The slides of 96 patients with a positive SNB were available for histopathologic review and correlation with clinical features and follow-up.
Baseline parameters of the 96 patients are summarized in Table 1 and Supporting Information Table 1 . Median and mean age was (59.0 and 56.6 6 12.6) years (range 24-84 years). Sex distribution was similar, with 42.7% females and 57.3% males. Median Breslow thickness was 2.20 mm (range 0.70-9.00). Median follow-up time was 53.0 months (range 1.0-145.9). Twenty-six (27.1%) of the patients were deceased and 40 (41.7%) had suffered from a recurrence during follow-up. showed that the separation of both groups was widest for the chosen binary classifcation of SN-MMR (<1 vs. 1). On Logrank analysis, the binary SN-MMR (<1 vs. 1 mitoses/mm 2 ) classification displayed a highly significant correlation with OS (p < 0.0001) while cut off points of 2 (p 5 0.0002) and 3 (p 5 0.0148) showed slightly weaker significance (Table 3) . When directly comparing the classification systems, 80.8% of the cases with a MTD >1 mm (i.e. RIII according to the Rotterdam classification) and 55.9% of the cases with a TPD >1 mm displayed a SN-MMR 1. On the other hand, 8.6% of the cases with a MTD 1 mm and 12.9% of the cases with a TPD 1 mm also displayed a SN-MMR 1. However, there was no RI SNB with a SN-MMR 1. Thus, the lack of a very strong correlation of the classification systems based on MTD, TPD, and SN-MMR indeed resulted in a remarkable shift of patients between the high-and low-risk groups indicating that their prognostic value may also differ.
Survival
First, univariate analyses (Cox-regression) were performed to test associations between clinicopathological characteristics of the primary melanoma (Breslow Index) and histopathological criteria and classifications of the SN (MTD, TPD, SN-MMR and the number of positive sentinel nodes) with overall (OS), melanoma-specific (MSS) and disease-free survival (DFS). The Breslow Index, MTD, TPD, SN-MMR and the number of positive sentinel nodes all significantly correlated with OS and MSS (Table 4) . Furthermore, all aforementioned parameters except for the number of positive sentinel nodes also correlated significantly with DFS (Table 4) . Univariate analysis of the classification of the primary melanoma and of the SNB demonstrated that the pT stage, S-, Dewar, Rotterdam, Hannover and Hannover II classifications significantly correlated with OS, MSS and DFS (Table 5) . Surprisingly, a binary classification based on the SN-MMR (<1 vs. 1 mitoses/mm 2 ) displayed a highly significant correlation with OS, MSS and DFS (p < 0.0001) and allowed an improved discrimination of patients with slowly and rapidly progressive disease on Kaplan Meier analyses as compared to both the binary classification systems using TPD and MTD (<1 mm vs. 1 mm) and the other, more complex classification systems (Table 5 , Fig. 2 ). The better discriminatory power of the binary classification based on the SN-MMR is also reflected by the higher hazard ratio in comparison with binary classifications based on MTD and TPD (Table 5) .
Furthermore, the aforementioned SN parameters and classification systems were subjected to multivariate CoxRegression analyses. These analyses identified the binary SN-MMR classification system as the strongest independent prognostic parameter for all three clinical endpoints (p < 0.0001 for OS, p 5 0.0001 for MSS and p 5 0.0006 for DFS) ( Table 6 ). For patients with a SN-MMR 1/mm 2 , the prognosis was far worse with 5-year MSS and DFS rates of 45.5% and 22.2%, respectively, as compared to patients with a SN-MMR 0/mm 2 (87.9% and 67.3%, respectively), when KaplanMeier analyses were performed (Fig. 2 , Table 5 ). None of the other classification systems showed a similar discriminative power to stratify patients with slowly and rapidly progressive disease with regard to OS, MSS and DFS. To assess whether the inclusion of SN-MMR in the multivariate analyses indeed resulted in improved quality of the model, analyses were performed with and without inclusion of SN-MMR and SN-MMR (binary). Akaike information criteria (AIC) for each endpoint (OS, MSS, DFS) were lower for the models including SN-MMR and SN-MMR (binary) in comparison to the respective models without the two parameters ( Table 6 ). As lower values of the AIC indicate a higher relative quality of a statistical model these findings provide statistical evidence that inclusion of the SN-MMR indeed provided additional information and thereby improved the prognostic quality for all endpoints analyzed.
Scores combining SN-MMR with either the parameters of the S-or Rotterdam classification systems or with various cut-off points for TPD and MTD have also been assessed. However, in our cohort none of these modified or combined scores revealed a better discrimination of patients with slowly and rapidly progressive disease than the SN-MMR classification alone (data not shown). This finding is in line with the multivariate Cox regression analysis which showed that the SN-MMR classification is the strongest independent prognostic factor while all other parameters except for the Dewar criteria (p 5 0.0105 for DFS) and the number of positive sentinel nodes (p 5 0.0204 for OS and p 5 0.0090 for MSS) provided no additional information and hence were not significantly correlated to the outcome (Table 6 ). Thus, multivariate Cox regression analysis also supports the notion that combinations of the SN-MMR classification with classification systems based on TPD or MTD will likely not improve discriminative power.
Discussion
Positivity of the SN is still regarded as the single most important prognostic factor in intermediate thickness melanoma patients. 6 Nevertheless, there is still a tremendous heterogeneity with regard to disease progression and survival among SN-positive melanoma patients. In light of the rising numbers of novel therapies, it appears mandatory to better discriminate between SN-positive melanoma patients with slowly and rapidly progressive disease to identify those who may specifically benefit from early adjuvant therapy in clinical trials. Therefore, a broad array of histopathological parameters and classification systems was assessed in our cohort of SN-positive melanoma patients and correlated with survival and disease progression.
Despite the fact that all published SN classification systems showed a significant correlation with prognosis in at least some of their subgroups, their discriminative power to 
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separate patients with slowly and rapidly progressive disease differed markedly. Notably, our data showed that a simple binary classification based on the sentinel node mitotic rate (SN-MMR) with similar cut-off points as used in the AJCC 2009 classification of primary melanomas had the highest discriminatory power to separate patients with slowly and rapidly progressive disease. The mitotic rate (MR) was first described as prognostic parameter for primary melanomas by Schmoeckel and Braun-Falco in 1978. 19 Subsequently, the simple hot spot method used to determine MR was already recommended for the reporting of primary melanomas in the 1980s. 20 Nevertheless, the reporting of the MR of primary melanomas was not widely performed until the release of the AJCC 2009 classification that included the MR to subclassify thin melanomas. 18 To our knowledge, this study is the first to assess the feasibility and prognostic significance of the SN-MMR. The study is partly limited by its monocentric and retrospective design and the potential difficulty of interobserver reproducibility of the SN-MMR especially in very small or diffusely distributed metastatic clusters that may only be positive on IHC. Nonetheless, assessment of the SN-MMR can be similarly performed as recommended for primary melanomas. However, caution needs to be exercised to avoid counting of mitoses of surrounding inflammatory cells. To circumvent this pitfall, careful correlation of H&E stained sections and sections stained by immunohistochemistry for melanocytic markers (e.g. HMB45, Melan-A) is advisable (Fig. 1) . To avoid very rare cases of false negative melanomas extended panels with additional melanocytic markers may also be included. Despite its inclusion into the AJCC 2009 classification as a decisive parameter, there is an ongoing debate about the feasibility and reproducibility of MR determination in thin primary melanomas. Two studies found good to excellent interobserver reproducibility when analyzing pT1 melanomas 21 and primary melanomas of all stages (pT1-pT4), 22 while a recent study found unsatisfactory inter-and intraobserver reproducibility when looking at pT1 and pT2 melanomas. 23 Similarly, the general prognostic value of the MR in primary melanomas [24] [25] [26] [27] has been demonstrated in several studies, while others were unable to provide statistical evidence that a MR >0 in a thin primary melanoma is significantly correlated with an increased risk of a positive SN. 24, 25, 27 Nonetheless, the utility of the MR and its impact on treatment decisions should be assessed in each setting independently as the general prognostic value of the MR in primary melanomas of all stages [24] [25] [26] [27] and also its value in the assessment of atypical melanocytic tumors 28, 29 has been demonstrated in several studies. In our opinion, the assessment of the SN-MMR is not comparably difficult as the assessment of the MR in thin primary melanomas. We used a standardized approach to measure SN-MMR that can easily be integrated into the routine evalution of SN without an additional major time delay.
In our cohort, the SN-MMR ranged from 0 to 15 mitoses/ mm 2 . Although the absolute number of mitoses/mm 2 significantly correlated with OS, MSS and PFS, a simple binary classification of <1 vs. 1 mitoses/mm 2 was able to efficiently discriminate between patients with slowly and rapidly progressive disease. This binary classification has two advantages. Firstly, it is identical to the classification used for primary melanomas and can thus be easily memorized. Secondly, interobserver reproducibility may be higher as the proper identification of a single mitosis is sufficient for classification while the exact value of the MR (mitoses/mm 2 ) may be prone to more variability due to intensity of analysis and microscope settings. Nevertheless, inter-observer reproducibility of the identification and quantification of the SN-MMR should be addressed in future studies as it has been done for established quantitative tumor burden parameters of the SN, which show a good to excellent interobserver agreement. 30 IHC with melanocytic markers is currently routinely performed in the evaluation of the SN. Therefore, a combination of antibodies that label mitoses (e.g. anti-phosphohistone H3) and melanocytes could be implemented to potentially improve accuracy and speed of the SN-MMR measurement. However, it is known that the MR of primary melanomas assessed by IHC is approximately twofold higher than the MR assessed by H&E staining 31 and another study showed that the implementation of the same IHC could not replace assessment by H&E and was not time-efficient. 21 Therefore, n/a 3.190 0.199-51.189 0.4127 6 100% 100% n/a n/a n/a n/a 6 83% 83% Even though there was a significant correlation between the SN-MMR and the parameters of sentinel tumor burden, it was not very strong as Spearman's correlation coefficients of 0.5 to 0.7 were found. Therefore, mitoses were clearly more common in larger metastases and in solid tumor cell aggregates. However, large and solid aggregates without mitoses as well as smaller aggregates with mitoses were also found, demonstrating that the SN-MMR is not just a surrogate marker of tumor burden. Binary classifications based on MTD, TPD and SN-MMR therefore resulted in considerably different subdivisions of high-and low-risk groups. Overall, it is simple and fast to determine the SN-MMR and its implementation into routine practice does not necessitate additional technical requirements or costs. Thus, we propose to include the SN-MMR in all pathology reports of SNB of melanoma patients without any delay to further evaluate its prognostic value in larger cohorts of SN-positive melanoma patients.
Patients with SN-MMR 1 mitoses/mm 2 had lower OS, DSS and DFS than the most advanced stages of most other classifications. Only extensive disease according to the Dewar criteria and stage 3 disease according to the Hannover I and II systems displayed similar disease courses. In the advanced stages of the other classification systems, however, patient numbers were a lot lower in comparison with the group of patients with SN-MMR 1 mitoses/mm 2 . This latter group comprised almost a third of all patients indicating that the sensitivity and specificity to detect patients with rapidly progressive disease is highest for the classification based on the SN-MMR (Table 5 ). The advantage of the SN-MMR classification is especially obvious when binary classifications of TPD, MTD and SN-MMR were compared using KaplanMeier analyses (Fig. 2) . Despite the fact that lower and higher stages of all three binary classification systems comprised similar numbers of patients, distinction between both groups was by far highest for SN-MMR, as indicated by the spread of Kaplan-Meier curves (Fig. 2) and the respective hazard ratios (Table 5) . Furthermore, comparison of Akaike information criteria (AIC) also provided statistical evidence that indeed prognostic models that include the SN-MMR provided higher predicitive quality than models without it (Table  6 ). It appears reasonable to us that incorporation of a surrogate parameter for proliferative activity may be able to provide additional prognostic information in comparison to mere measurements of size or extension as these parameters may be biased by the different time intervals between initial seeding and diagnosis. Increased SN-MMR may indicate both: either a large tumor burden (due to high proliferative activity or long time of tumor growth) or a low tumor burden with high proliferative activity. On the other hand, a SN-MMR <1 may either indicate a large tumor with very low proliferative activity (in this case pure measurement of tumor burden may overestimate the aggressiveness of the tumor) or a small tumor burden (due to low proliferative activity or short time of tumor growth). The additional prognostic value may especially be noticeable for S3/R3 deposits with SN-MMR <1 and S2/R2 deposits with SN-MMR 1.
The distribution of patients among the different stages of the different classification systems and their respective prognosis in our cohort was very similar to the findings published in the literature. High congruence was especially seen with regard to the S-, 11 Rotterdam, and Hannover I and II systems. 12, 13 Our data therefore confirm the prognostic significance and reproducibility of these classification systems and indicate that the analyzed cohort did not inherently differ from the published cohorts of SN-positive melanoma patients. Thus, it appears reasonable to believe that our findings will also be applicable in a similar fashion to other cohorts of SN-positive patients.
Despite the fact that further multi-centric analyses are of course necessary to evaluate and compare the different classification systems and parameters and to finally delineate which parameters, cut off points or combinations thereof are best to classify positive SN of melanoma patients, we believe that our findings should have immediate practical implications. Firstly, as the assessment of the SN-MMR is simple and cost-effective, it should be immediately incorporated into routine pathology reports of sentinel nodes of melanoma patients. Secondly, most current drug trials investigating adjuvant therapy of stage 3 melanoma patients consider a MTD >1 mm as inclusion criterion. Our data indicate that this binary classification of patients is inferior to a classification based on the SN-MMR. We therefore propose that these trials should incorporate the use of the SN-MMR to assess its value in selecting the appropriate patient cohort which might benefit from adjuvant therapy. Cancer Therapy and Prevention
